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length-of-stay was 15.8 days (15.0 days for DVT patients and 17.0 days for PE pa-
tients). The mean total cost was Chinese Yuan (CNY) 16487.91 (median:9039.10,
IQR:5128.80-18981.83), CNY 17698.61 (median:8643.68, IQR:5025.03-19594.93) in pa-
tients with DVT and CNY 14523.39 (median:9879.25, IQR:5870.43 -ee18630.41) in
patients with PE. The average drug cost accounts for 47.4% of the total cost (mean:
6340.29; median:4479.94, IQR:2279.88-7991.12).The multiple linear regressions
showed that patients from tertiary hospitals had 105% higher costs than those
from primary hospitals (P  0.001), and patients from municipalities had 48.6%
higher costs than those from prefecture-level cities (P 0.01). CONCLUSIONS: The
costs per hospitalization associated with DVT or PE events are substantial. Hospi-
talization costs are now driven predominantly by the cost of drugs, levels of hos-
pitals and cities.
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HOSPITAL BASED COST SURVEY OF ACUTE CORONARY SYNDROME IN SOUTH
KOREA
Kim BRM
Seoul National University, Seoul, Seoul, South Korea
OBJECTIVES: Acute coronary syndromes (ACS) consist mainly of ST-segment ele-
vation myocardial infarction (STEMI) and unstable angina (UA)/non-STEMI
(NSTEMI). ACS showed an enormous medical, social, and economic burden world-
wide. ACS in the form of myocardial infarction is responsible for almost half of all
deaths related to cardiovascular disease. South Korea compared to the OECD coun-
try average, shows high cardiovascular morbidity and mortality, and the recur-
rence rate is increasing every year. We examined the direct cost of hospitalization
for ACS which planned percutaneous coronary intervention (PCI) using medical
cost survey in South Korea.METHODS:We conducted a cost survey to examine the
actual direct medical costs of the team of cardiologists, technicians of intervention
and reimbursement reviewers in the hospital. To examine the cost data of a pa-
tients who received procedures, operations and admissions. We could select index
patient cases through medical chart review as he/she had ever been visited the
hospital since last 1 year. Through delphi panel discussion and reviewing, we
refined the cost data excluding non-related ACS treatment in index case. RESULTS:
It is the first survey of the actual cost in ACS. The totalmedical cost for ACS patients
who have undergone the procedure was 4.451 million Korean won. The cost is
lower level if considering difficulties in surgery. But among the components in ACS,
the cost of stents and devices were largely accounted for the total cost.
CONCLUSIONS: The medical cost of ACS in Korea is a burden to both patients and
society, due to increasing recurrence in cardiovascular disease. Among the total
cost, the cost of stents is higher than the inpatient cost. This is one of the reasons
of the highmedical cost in ACS. This result will have as implication the adjustment
of the cost of stents and devices in ACS treatment in South Korea.
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PHARMACIST’S INVOLVEMENT IN A MULTIDISCIPLINARY ISCHEMIC STROKE
TEAM IN AND ITS ASSOCIATED COST AVOIDANCE
Tsai YJ, Leu WJ, Lin YM, Lu TH
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OBJECTIVES: Stroke is amajor cause of death around the world. This study aims to
evaluate the quality of care in pharmacist’s participation in a multidisciplinary
ischemic stroke team, and the potential cost avoidance associatedwith the recom-
mendations made by clinical pharmacists.METHODS:We conduct a retrospective
study at a stroke center with pharmacist participation in medical rounds. Six hun-
dred and forty-eight patients who suffered with stroke attack 10 days before ad-
mission are enrolled into sample. Data collects from November 2008 to September
2010. The patients with hemorrhage stroke are excluded from sample. Quality of
acute stroke care is assessed by five pharmaceutical care-related performance in-
dicators according to American Heart Association/American Stroke Association
Get With the Guidelines-Stroke program (GWTG-Stroke). The cost avoidance is
measured by the scored probability of harm. RESULTS: Study results show that
there is significantly improved in four performance indicators in the year of 2010
and 2008. Indicators with significant improvement include intravenous thrombo-
lytic (24.00% vs. 00.00%), early and discharge antithrombotic (95.93% vs. 93.33%,
96.56% vs. 93.18%), and anticoagulation for atrial fibrillation (71.43% vs. 20.00%).
The indicator of prescribing rate of lipid-lowing medications, however, remains
stable over two separate periods (51.70% versus 52.70%) due to the restriction of the
National Health Insurance Policy. The assumption that cost of prolonged length of
hospital stay due to ADE is about $5000 NTD. Therefore, cost avoidance was NT
$2,207,816 NTD in this study. CONCLUSIONS: This study demonstrates that phar-
macists involvement in a multidisciplinary ischemic stroke team are associated
with facilitating the quality of care and increasing potential cost avoidance.
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ECONOMIC EVALUATION OF EZETIMIBE CO-ADMINISTRATION FOR HIGH
CORONARY HEART DISEASE (CHD) RISK PATIENTS NOT AT GOAL WITH
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1MSD (Thailand) Ltd., Bangkok, Thailand, 2Merck & Co. Inc., Whitehouse Station, NJ, USA,
3Merck & Co. Inc., Upper Gwynedd, PA, USA
OBJECTIVES: To evaluate cost-effectiveness of adding ezetimibe to simvastatin
versus a switch to rosuvastatin or atorvastatin for high CHD risk patients who
cannot attain treatment goal (LDL-C  100 mg/dL) on their current simvastatin
dosage from Thai payer perspective.METHODS: A published Markov model (Cook
et al. 2004) was used to project lifetime costs and outcomes of lipid-lowering treat-
ment in primary and secondary CHD prevention. Lipid efficacy data were obtained
from clinical trials. Risks of CHD events and non CHD-related mortality rates were
estimated by using Framingham Heart Study risk equations and information from
Ministry of Public Health (MOPH), respectively. Disease-related costswere obtained
from published local studies. Drug prices were those published by MOPH. All costs
were expressed in THB 2010 values. Future costs and outcomes were discounted at
3%. Two scenarios were compared in the analysis: the addition of ezetimibe to
simvastatin 20 mg versus switching to rosuvastatin 10 mg and the addition of
ezetimibe to simvastatin 40 mg versus switching to atorvastatin 40 mg. RESULTS:
Ezetimibe co-administration increased life expectancy (LY) by 0.15 and 0.26 years
and resulted in 0.07 and 0.12 additional quality-adjusted life years (QALY) when
compared to a switch to rosuvastatin and a switch to atorvastatin, respectively.
The QALY gained would yield lifetime cost-savings of Baht 1,106 and 2,137 per
patient for such comparisons. Similar results were obtained where costs and out-
comes were either discounted or undiscounted. The sensitivity analyses showed
that results were robust to changes across scenarios. CONCLUSIONS: This analysis
suggested that addition of ezetimibe to simvastatin is the dominant treatment
strategy (more effective and less costly) in both scenarios. The results are very
imperative to assist policy decision-making in order to increase access to second-
line treatment option for patients not achieving lipid treatment goals with simva-
statin monotherapy in Thailand.
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THE PRACTICAL ASSESSMENT OF SAME-DAY DISCHARGE WITH SCHEDULED
TRANS-RADIAL PERCUTANEOUS CORONARY INTERVENTION
Syu FK
Han-Ming Hospital, Changhua City, Taiwan
OBJECTIVES: In response to TW-DRG implementation, based on safety, through
the radial artery cardiac catheterization intervention, how to make patients dis-
charged earlier, save health care costs and create a win-win between patients and
hospitals.METHODS: In this retrospective study in Han-Ming Hospital, Taiwan, we
enrolled 282 cases from January 1, 2006 to December 31, 2010. RESULTS: In the
admission less than 24 hours after the PCI treatment, there were 129 males and 51
females (64.312.5 years, mean s.d.). Besides, in other group over 24 hours, there
were 74 males and 28 females (69.111.5 years). Using Logistic Regression Analysis,
age65 years (RR 1.683, 95%CI 1.943-3.031, p-value 0.010,OR: 2.647,95%CI: 1.009-6.941,
p-value 0.030)eATroponin-I 1 ug/L(RR 1.963, 95%CI 1.254-15.155, p-value 0.001,OR:
2.053, 95%CI: 1.240-17.601, p-value 0.004)eAlesion numbers 2(RR 1.402, 95%CI 1.330-
5.955, p-value 0.001,OR:1.128, 95%CI: 1.120-10.617, p-value 0.008)eATreatments using
stents (RR 1.963, 95%CI 1.254-15.155, p-value 0.018,OR: 4.688, 95%CI:1.443-15.232, p-
value 0.033)eAvascular type such as A & B1 (RR 1.683, 95%CI 1.037-2.731, p-value
0.017,OR: 2.569, 95%CI: 1.751-8.794, p-value 0.036)eAnon-complication (RR 2.153,
95%CI 1.979-4.473, p-value 0.039,OR: 3.891, 95%CI: 1.011-25.801, p-value 0.043).
CONCLUSIONS: If patients have characteristics like age 65 years, Troponin-I 1
ug/L, lesion numbers less than 2, using stents, vascular type diagnosed as A and B1,
and non-complication, they could tend to discharge in 24 hours after PCI treat-
ment.
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A PHARMACOECONOMIC ASSESSMENT OF RECOMBINANT TISSUE
PLASMINOGEN ACTIVATOR THERAPY FOR ACUTE ISCHEMIC STROKE IN A
TERTIARY HOSPITAL IN CHINA
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OBJECTIVES: To conduct a pharmacoeconomic assessment of thrombolysis by in-
travenous recombinant tissue plasminogen activator (rt-PA) therapy for acute isch-
emic stroke (AIS) in a tertiary hospital in China.METHODS:A retrospective analysis
was conducted usingmedical records data among patients hospitalized for AIS and
receiving rt-PA therapy (time window: 6 hours after AIS) from September 2007 to
September 2008. A conservative therapy group (including antiplatelet, anticoagu-
lation, statin, traditional Chinesemedicine) werematched (1:1) on age, gender, risk
factors (hypertension, diabetes, previous stroke/TIA, high cholesterol/lipids and
coronary heart disease), Glasgow Coma Scale (GCS) and National Institutes of
Health Stroke Scale (NIHSS). Two groups were compared on 14th-day clinical out-
comes, utilities estimated from modified Rankin Scale (mRS) scores, and costs.
RESULTS: Forty patients (65%male, age 6511 years) in rt-PA and 40 patients (58%
male, age 6911 years) in conservative group were included. No differences were
found in mortality between 2 groups. Among survivors on 14th day, NIHSS
(meanSD: 1.892.64 vs. 4.385.57; P0.018 and mRS (0.771.26 vs. 1.921.80;
P0.002) were lower in rt-PA (N37) than conservative group (N39). Barth Index
(BI) was higher in rt-PA group (90.5716.71 vs. 74.3625.88; P0.002). Hospital
length-of-stay (LOS) was shorter in rt-PA (15.47.8 days) than conservative group
(19.28.80 days; P0.05). Total costs were not significantly different:
¥22,82611,049 (rt-PA) vs. ¥18,60510,713 (conservative), while total drug costs
were higher in rt-PA (¥13,3794,765) than conservative group (¥10,2256,222)
(P0.017). No difference was found in cost of hospital care (¥2,5742,608 vs.
¥2,2752,723), laboratory exam (¥1,8541,037 vs. ¥1,867974), etiology exam
(¥2,335823 vs. ¥2,1251,156) and traditional Chinese medicine (¥354266 vs.
¥278266) between rt-PA and conservative group. Utility gained with rt-PA was
0.04 (0.61 vs. 0.57). CONCLUSIONS: Intravenous rt-PA was associated with lower
patients’ disabilities, less hospital days, and comparable total costs compared to
conservative therapy for the management of AIS in this study population.
PCV26
LIFETIME COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS
WITH ACUTE CORONARY SYNDROMES BASED ON THE PLATO TRIAL: A
SINGAPORE HEALTH CARE PERSPECTIVE
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OBJECTIVES: Ticagrelor is a reversibly binding oral P2Y12-receptor antagonist de-
veloped for reduction of thrombosis. The PLATO trial compared ticagreloraspirin
to clopidogrelaspirin in individuals with acute coronary syndromes (ACS); ti-
cagrelor was superior on the primary composite endpoint of cardiovascular death,
myocardial infarction (MI) or stroke, without an increase in major bleeding events.
The current study estimates the lifetime cost-effectiveness of ticagrelor relative to
generic clopidogrel fromaSingapore public health care perspective.METHODS: For
the analysis of cost-effectiveness, a two-part cost-effectiveness model was used.
The first part was a 12-month decision tree using PLATO trial data to estimate rates
ofmajor cardiovascular events, health care costs, and health-related quality of life.
The second part was a Markovmodel estimating lifetime quality-adjusted survival
and costs conditional on whether a non-fatal MI, a non-fatal stroke, or no MI or
stroke occurred during the initial 12 months. The model applied a lifetime horizon
to calculate mean direct medical costs and QALYs. The results are presented as
incremental cost-effectiveness ratios (ICER’s). Daily costs of SGD1.10 for generic
clopidogrel and SGD6.00 for ticagrelorwere applied.We calculated short term costs
by applying Singapore unit costs, and costs from a comparable Asian country (Ko-
rea) to derive the Markov costs. Probabilistic sensitivity analysis was performed.
RESULTS: Ticagrelor was associated with a lifetime QALY gain of 0.13, primarily
driven by lower cardiovascular mortality. The resulting incremental cost per QALY
gained was SGD10,136 from the public sector perspective. Probabilistic sensitivity
analysis indicated that ticagrelor had more than 99% probability of being cost-
effective given the recommended WHO willingness to pay threshold of one GDP/
capita or SGD56,000 per QALY. CONCLUSIONS: Based on the PLATO trial data, one
year treatment with ticagreloraspirin versus generic clopidogrelaspirin in ACS
patients, relative to WHO reference standards, is cost-effective from a Singapore
public health care perspective.
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COST-EFFECTIVENESS OF LEFT ATRIAL APPENDAGE OCCLUSION DEVICE FOR
STROKE PREVENTION IN ATRIAL FIBRILLATION
Lee VW1, Chow IHI2, Yan B2, Yu CM1, Lam YY2
1The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 2The Chinese University of Hong
Kong, Shatin, Hong Kong
OBJECTIVES:To estimate the long-time cost-effectiveness of Left Atrial Appendage
(LAA) occlusion device for preventing stroke in a hypothetical cohort of 65-year-old
patientswith atrial fibrillation (AF).METHODS:Adecision analyticmodel was used
to perform a cost-effectiveness analysis comparing LAA occlusion device and 5
alternative anticoagulant therapies from a health care provider perspective. Treat-
ment strategies for AF are included Aspirin, dual therapy with Aspirin and Clopi-
dogrel, Warfarin, Dabigatran 150mg or 110mg, and LAA occlusion device. The pa-
rameters including rate of adverse events, utility, and costs were derived from the
ACTIVE trial, RE-LY trial, PROTECT trial, and published references in our model.
Outcomes are quality-adjusted life years (QALYs), lifetime costs, and incremental
cost-effectiveness ratios (ICERs). Costs and QALYs were discounted at an annual
rate of 3%. One way sensitivity varied by the CHADS2score and probabilistic sen-
sitivity analyses (PSAs)were conducted to assess parameter uncertainty. RESULTS:
Compared with Aspirin, LAA occlusion device, Warfarin, Dabigatran 150mg and
110mg were cost-effective. The ICERs were US$975 per QALY with LAA occlusion
device, US$4,982 per QALY with Warfarin, US $10,672 per QALY with Dabigatran
150mg, US$10,972 per QALY with Dabigatran 110mg. When using Warfarin as a
comparator, LAA occlusion device is less costly and more effective, Dabigatran
150mg cost US$28,556 per QALY, and Dabigatran 110mg cost UD$37,328 per QALY.
For patient with CHADS2 score of 0, 1, 2, 3, or 3a4, the ICREs of LAA occlusion device
over Aspirin were US$1,257 per QALY, US$1,104 per QALY, US$894 per QALY,
US$626 per QALY, US$518 per QALY, respectively. LAA occlusion device was cost-
effective over 95% of theMonte Carlo simulation using a cost-effectiveness thresh-
old of US$50,000 per QALY.CONCLUSIONS:The LAA occlusion device is considered
cost-effective compared with Aspirin, Warfarin, Dabigatran 150mg or 110mg in AF
patients.
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COST-EFFECTIVENESS OF PRESENTATION AND DELAYED TROPONIN TESTING
FOR ACUTE MYOCARDIAL INFARCTION
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OBJECTIVES: To estimate the cost-effectiveness of delayed troponin testing for
myocardial infarction (MI), as recommended in current guidelines, compared to
troponin testing and other biomarkers at presentation.METHODS:Wedeveloped a
decision analytic model to estimate the cost-effectiveness of diagnostic strategies
for MI, measured as the incremental cost per quality-adjusted life year (QALY)
gained by each strategy compared to the nextmost effective alternative. Themodel
was applied to a hypothetical population of 1000 patients attending hospital with
symptoms suggesting MI but a normal or non-diagnostic electrocardiogram (ECG)
and no major co-morbidities requiring hospital treatment. Sensitivity and speci-
ficity of the strategieswere estimated bymeta-analysis of diagnostic cohort studies
of presentation troponin T. The risk of reinfarction and death (with and without
treatment) was determined using data from a study by Mills et al, Lifetime QALYs
were estimated from life expectancy and corresponding annual utilities. The dis-
counted life expectancy of patientswithMI andMIwith reinfarctionwas estimated
from Polanczyk et al, while the utility of patients withMIwas estimated fromWard
et al. RESULTS: In all scenarios tested presentation high sensitivity troponin test-
ing was the most effective strategy with an incremental cost-effectiveness ratio
(ICER) below the £20,000/QALY threshold. Delayed troponin testing was only likely
to be cost-effective if a discharge decision could be made as soon as a negative
result was available and the £30,000/QALY threshold was used. CONCLUSIONS:
Delayed troponin testing is unlikely to be cost-effective compared to high sensitiv-
ity troponin testing at presentation in most scenarios. Current guidelines recom-
mending 10-12 hour troponin testing does not appear to promote cost-effective use
of hospital resources, unless services are in place to allow rapid decision making
once delayed test results are available.
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LONG-TERM COST-EFFECTIVENESS OF TICAGRELOR IN PATIENTS WITH ACUTE
CORONARY SYNDROME IN THAILAND
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OBJECTIVES: The PLATO trial showed that ticagrelor significantly reduced the rate
of cardiovascular mortality, myocardial infarction, or stroke compared to clopi-
dogrel in patients with acute coronary syndrome (ACS) with additional drug cost.
Critical appraisal is necessarily important to justify adopting this new treatment in
the era of limited health care resources. This study aimed to evaluate long-term
cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus clopidogrel
plus ASA in ACS patients in Thailand. METHODS: A two-part decision-analytic
model, comprising a one-year decision tree and a long-term Markov model, was
constructed to estimate lifetime costs and quality-adjusted life years (QALYs) from
Thai health care payer’s perspective. For the first year, data from PLATOwere used
to estimate rate of cardiovascular events, resource use, and QALYs. For year two
and onwards, clinical effectivenesswas estimated conditional on individual health
states occurred during the first year. Unit costs were based on Thai database. All
costs presented in year 2011 and effects were discounted at 3% per annum. A series
of sensitivity analyses were performed to assess robustness of the model.
RESULTS: The incremental cost -effectiveness ratios (ICERs) with ticagrelor were
312,044 and 79,979 THB/QALY compared to generic and branded clopidogrel, re-
spectively. Probabilistic sensitivity analysis indicated that ticagrelor has high prob-
abilities of being cost effective compared to generic (85.0%) and branded clopi-
dogrel (99.9%) at a willingness to pay threshold of 3 times GDP/capita.
CONCLUSIONS: It might be appropriate to assert that ticagrelor is an economically
valuable treatment of ACS within the Thai context.
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COST-EFFECTIVENESS OF CILOSTAZOL, NAFTIDROFURYL OXALATE,
PENTOXIFYLLINE AND INOSITOL NICOTINATE FOR THE TREATMENT OF
INTERMITTENT CLAUDICATION IN PEOPLE WITH PERIPHERAL ARTERIAL
DISEASE IN THE UK
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Peripheral arterial disease (PAD) is a condition in which there is blockage or nar-
rowing of the arteries that carry blood to the peripheries. Themost common symp-
tom of PAD is intermittent claudication (IC), characterised by pain in the legs on
walking that is relieved with rest. Symptoms of IC can be managed with exercise
therapy and/or vasoactive drugs. OBJECTIVES: To assess the cost-effectiveness of
the vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol
nicotinate for IC due to PAD in adultswhose symptoms continue despite a period of
conservativemanagement.METHODS:AMarkov decisionmodel was developed to
assess the lifetime costs and benefits of each vasoactive drug compared with no
vasoactive drug andwith each other. Regression analysiswas undertaken tomodel
the relationship betweenmaximumwalking distance and utility based on patient-
level data from a trial of cilostazol to enable quality of life impacts to be estimated
for the other drugs under consideration. Resource use data were sourced from the
literature and a comprehensive sensitivity analysiswas undertaken.RESULTS:The
economic evaluation suggests that naftidrofuryl oxalate is more effective and less
costly than cilostazol and pentoxifylline and has an estimated cost per QALY
gained of around £6070 compared with no vasoactive drug. Whilst there is limited
effectiveness evidence associated with inositol nicotinate, threshold analysis sug-
gests that it is unlikely to be considered to be cost-effective due to its more expen-
sive acquisition cost.CONCLUSIONS:This is the first published cost-utility analysis
in this areawhich extrapolates data over a lifetime and uses effectiveness evidence
from a network meta-analysis. In contrast to previous guidelines recommending
cilostazol, this comprehensive analysis suggests that naftidrofuryl oxalate is the
only vasoactive drug for PAD which is likely to be cost-effective at a willingness to
pay threshold of £20,000 per QALY gained.
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COST-EFFECTIVENESS OF APIXABAN VERSUS ENOXAPARIN FOR THE
PREVENTION OF POSTSURGICAL VENOUS THROMBOEMBOLISM IN KOREA
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OBJECTIVES: To evaluate the cost-effectiveness of apixaban versus enoxaparin in
the prevention of venous thromboembolism (VTE) after total hip replacement
(THR) and total knee replacement (TKR) from the perspective of the Korean health
care system.METHODS:Adecision treemodel was developed to simulate the costs
and outcomes of VTE prevention, and consisted of 3 phases- 1) prophylaxis phase;
2) post-prophylaxis phase (up to 90 days); and 3) long-termcomplications phase (up
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